Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

VERSITI MICHIGAN INC

UEI: GYWNKQJ5NA81CAGE: 686Q4

VERSITI MICHIGAN INC is a federal contractor, registered under UEI GYWNKQJ5NA81 and CAGE code 686Q4. It has been awarded $152,173 in federal contracts. Primary work spans Blood and Organ Banks. Top awarding agencies include Department Of Veterans Affairs.

Contact Information

Registration and classification details

Registration

UEI Code

GYWNKQJ5NA81

CAGE Code

686Q4

Entity Structure

Corporate Entity (Tax Exempt)

Established

N/A

Business Classifications

Non-Profit Organization

NAICS Codes

621991Blood and Organ Banks(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

VERSITI MICHIGAN INC operates as a specialized provider of healthcare support services within the federal contracting ecosystem, leveraging its primary NAICS classification of 621991 to deliver non-clinical, administrative, and operational solutions that underpin public health infrastructure. While ...

VERSITI MICHIGAN INC operates as a specialized provider of healthcare support services within the federal contracting ecosystem, leveraging its primary NAICS classification of 621991 to deliver non-clinical, administrative, and operational solutions that underpin public health infrastructure. While specific award details are not available, the NAICS code indicates a focus on medical and diagnostic laboratories, outpatient care centers, or other similar ambulatory healthcare support functions, suggesting capabilities in laboratory logistics, specimen handling, data management, and regulatory compliance support for government health programs. The company’s technical expertise likely includes quality assurance protocols, CLIA and CAP alignment, electronic health record integration, and workflow automation for high-volume clinical support environments. Its specialization appears centered on enabling efficient, compliant, and scalable healthcare delivery systems in settings requiring precision, audit readiness, and interoperability with federal health data standards. No agency relationships can be inferred due to insufficient award data, and no recent contract history is available to characterize patterns of engagement with federal departments. The company’s industry focus is narrowly defined by its primary NAICS code, positioning it within the outpatient and diagnostic support services segment of the federal healthcare market. This includes supporting government-funded testing, screening, and diagnostic programs that require rigorous documentation, chain-of-custody procedures, and adherence to federal health information privacy rules. VERSITI MICHIGAN INC is structured as an 8H entity, indicating it is a small business owned and controlled by a Native American individual or tribe, with its operational base in Grand Rapids, Michigan. The company holds no additional government certifications beyond its 8H status, and its geographic footprint is currently localized to Michigan, with potential to serve regional federal health initiatives. Its market positioning reflects a niche role in supporting public health infrastructure through compliant, operationally reliable support services.

Key Performance Metrics

Awards Count

14

All time

Active

0

Currently performing

Completed

14

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with VERSITI MICHIGAN INC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for VERSITI MICHIGAN INC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in VERSITI MICHIGAN INC's top NAICS codes and agencies

NAICS: 621991
New
Federal
BPA - Blood Transfusion Services
Solicitation # FA860127Q0015
Solicitation FA8601-27-Q-0015 is a combined synopsis and request for quotation for a Blanket Purchase Agreement (BPA) to provide blood components and reference lab transfusion testing services for the 88th Medical Group at Wright Patterson AFB, Ohio. The contract supports inpatient, outpatient, and emergency care, requiring the contractor to maintain FDA licensing, AABB standard compliance, and 24/7 availability, including a mission-critical one-hour turnaround for STAT deliveries. The BPA has a master dollar limit of 425,000.00 dollars, with individual purchase calls capped at 85,000.00 dollars, and a period of performance running from December 4, 2026, to October 5, 2031. Award will be made using the Lowest Price Technically Acceptable (LPTA) method to the lowest-priced offeror that meets all solicitation requirements and receives an acceptable rating for technical capability. This acquisition is not set aside for small businesses and falls under NAICS code 621991. Offerors must be registered in the System for Award Management (SAM) and meet a mandatory minimum CMMC Level 1 assessment. Quotes must be submitted electronically to the designated contract specialist and contracting officer by the specified deadline, including a completed Required Information Sheet and detailed descriptions of services to be considered for award.
FA8601 Aflcmc Pzio

POSTED

about 15 hours ago

DEADLINE

in 5 days
View Details
NAICS: 621991
Federal
Human Cadaver - Based Medical Training and Program Support Services for the 44th Medical Brigade stationed at Fort Bragg Army Base, North Carolina.
Solicitation # 0012468284
The Medical Acquisition Support Office – Alpha is seeking capable vendors to provide human cadaver-based medical training and program support for the 44th Medical Brigade. The scope of work includes the procurement and delivery of up to 20 ethically sourced, non-dissected perfused whole-body cadaver specimens annually, which must be serologically negative for HIV, Hepatitis B/C, and Syphilis. The contractor is responsible for providing refrigerated transportation to primary performance sites at Fort Bragg, NC; Fort Campbell, KY; Fort Stewart-Hunter Army Airfield, GA; and Fort Polk, LA. Additionally, the contractor must provide rental medical equipment and consumable Class VIII supplies, such as surgical packs, tourniquets, and simulated blood. The requirement includes providing highly qualified Subject Matter Experts (SMEs) to support up to 10 training events per fiscal year. These SMEs must be board-certified general surgeons with specific competencies in various trauma procedures, such as cricothyroidotomy and exploratory laparotomy, to serve as instructors and mentors. The anticipated contract structure consists of a base period followed by four one-year option periods. All personnel must comply with strict Installation Access Control System requirements, including Anti-Terrorism Level I and iWatch training, to gain access to military installations.
W40M MRC0 West

POSTED

11 days ago

DEADLINE

in about 18 hours
View Details
NAICS: 621991
Federal
6505--Human Blood and Blood Products
Solicitation # 36C25727Q0049
The Department of Veterans Affairs, Network Contracting Office 17, intends to award a single-award, firm-fixed-price Indefinite Delivery/Indefinite Quantity (IDIQ) contract to the South Texas Blood and Tissue Center. This procurement is for the supply and delivery of human blood and blood products, as well as guidance in clinical pathology procedures, to support the Audie L. Murphy Veterans Health Care Center within the South Texas Veterans Health Care System in San Antonio, Texas. The government is pursuing this as a sole source procurement under the authority of 41 U.S.C. 3304(a)(1) and FAR 6.103-1, asserting that only one responsible source can satisfy the agency's requirements. The contractor must maintain AABB and College of American Pathologists (CAP) accreditation and hold an unrevoked U.S. license from the FDA Bureau of Biologics. Key operational requirements include 24/7/365 availability and a tiered delivery system: STAT orders must be delivered within 60 minutes, ASAP orders within 2 hours, and routine orders within 24 hours. All products must be collected via closed systems under aseptic conditions, labeled according to the ABO Blood Group System and Rh type, and transported in compliance with FDA, AABB, and DOT regulations to ensure proper temperature maintenance. Acceptance of deliveries is based on STVHCS Blood Bank criteria, including physical appearance, contamination checks, and specific shelf-life minimums for red blood cells, plasma, and cryoprecipitate.
257-NETWORK Contract Office 17 (36C257)

POSTED

15 days ago

DEADLINE

in 7 days
View Details
NAICS: 621991
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute (NCI) has issued a Limited Competition Notice of Funding Opportunity (RFA-CA-28-004) to support the continuation of two critical biospecimen banking resources: the National Clinical Trials Network (NCTN) Biobanks and the Early-Phase and Experimental Clinical Trials (EET) Biobank. The primary objective is to maintain these national resources for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. These resources facilitate translational cancer research, biomarker development, and validation by providing essential specimens from NCI-funded clinical trials. The NCI intends to fund approximately six awards for fiscal year 2027, with a total estimated funding of 19 million dollars and a maximum budget of 3 million dollars in direct costs per year for a requested project period of six years. Applications will be evaluated through the NIH peer-review system based on scientific and technical merit, significance, and the adequacy of the institutional environment. Key requirements for applicants include maintaining active registrations in SAM, eRA Commons, and Grants.gov, as well as providing specific documentation regarding the current scale of operations, accomplishments, and standard operating procedures. Awardees must adhere to NCI Best Practices for Biospecimen Resources, federal human subjects regulations under 45 CFR 46, and strict cybersecurity incident reporting protocols, including notification of incidents within 48 hours of discovery. The scope of work includes managing secure informatics systems, providing specimen collection kits, and ensuring the availability of annotated biospecimens for authorized investigators.
National Institutes Of Health

POSTED

15 days ago

DEADLINE

in 3 months
View Details
NAICS: 621991
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.
National Cancer Institute

POSTED

15 days ago

DEADLINE

in 3 months
View Details